Profile data is unavailable for this security.
About the company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
- Revenue in USD (TTM)66.75m
- Net income in USD-214.86m
- Incorporated2011
- Employees273.00
- LocationADC Therapeutics SABiopole, route de la Corniche 3BEPALINGES 1066SwitzerlandCHE
- Phone+41 216530200
- Websitehttps://adctherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 291.74m | 13.00 | -- | 1.75 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 298.58m | 112.00 | -- | 0.8953 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 298.77m | 175.00 | -- | 1.17 | -- | 24.49 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| PepGen Inc | 0.00 | -89.14m | 304.71m | 64.00 | -- | 1.95 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 306.37m | 126.00 | -- | -- | -- | 2.25 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Solid Biosciences Inc | 0.00 | -90.69m | 308.76m | 88.00 | -- | 1.60 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 310.03m | 168.00 | -- | 0.8104 | -- | 7.64 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| ADC Therapeutics SA | 66.75m | -214.86m | 310.24m | 273.00 | -- | -- | -- | 4.65 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Biomea Fusion Inc | 0.00 | -139.65m | 315.39m | 112.00 | -- | 3.03 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 316.58m | 33.00 | -- | 1.37 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 321.30m | 304.00 | -- | 2.11 | -- | 1.90 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Editas Medicine Inc | 67.03m | -193.45m | 322.48m | 265.00 | -- | 1.39 | -- | 4.81 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 322.49m | 75.00 | -- | 0.6768 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Ocugen Inc | 8.19m | -45.87m | 328.16m | 65.00 | -- | 17.34 | -- | 40.06 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 331.80m | 57.00 | -- | 1.27 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to ADC Therapeutics SA's reporting currency: US Dollar USD
53.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 01 Jul 2024 | 28.66m | 29.66% |
| Prosight Management LPas of 30 Jun 2024 | 9.57m | 9.90% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.20m | 3.31% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.92m | 3.03% |
| SilverArc Capital Management LLCas of 30 Jun 2024 | 1.77m | 1.83% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 1.52m | 1.58% |
| Platinum Investment Management Ltd.as of 30 Jun 2024 | 1.30m | 1.34% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 1.21m | 1.25% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 1.02m | 1.05% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 991.30k | 1.03% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
